Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabeprazole Dosage and CYP2C19 in Chinese GERD Patients
NCT00354757Phase 4Completed
- Sponsor
- National Taiwan University Hospital
- Start
- Jun 2005
- Primary completion
- Jun 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rabeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by National Taiwan University Hospital. Primary endpoint: Symptom response with a four-grade daily record at 2 weeks. Started Jun 2005; status: completed.
02
Drugs
rabeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00354757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00354757.